In this section
@article{Dixon-Zegeye:2026:10.1038/s43856-026-01464-2,
author = {Dixon-Zegeye, M and Ramani, A and Walker, M and Stapley, J and Murdoch, ME and Murdoch, IE and Ozoh, GA and Mosser, JF and Basanez, M-G},
doi = {10.1038/s43856-026-01464-2},
journal = {Communications Medicine},
title = {Modelling of onchocerciasis-associated skin and ocular disease and the impact of ivermectin treatment},
url = {http://dx.doi.org/10.1038/s43856-026-01464-2},
volume = {6},
year = {2026}
}
TY - JOUR
AB - BackgroundDespite decades of control interventions in sub-Saharan Africa, morbidity associated with Onchocerca volvulus infection still exerts a substantial burden of disease, arising from cutaneous, ocular and neurological manifestations.MethodsWe developed and integrated a morbidity sub-model into our previously published individual-based, stochastic transmission model, EPIONCHO-IBM, including both reversible (severe itch, reactive skin disease (RSD)), and irreversible (skin atrophy, depigmentation, hanging groin) cutaneous sequelae, and eye disease (blindness, visual impairment). We modelled the relationship between onchocerciasis skin disease (OSD) and infection prevalence using pre-intervention data from northern Nigeria, and between onchocerciasis ocular disease (OOD) and infection intensity using data from the Onchocerciasis Control Programme in West Africa. We simulated the impact of ivermectin mass drug administration (MDA) upon OSD and OOD using data from Cameroon, Central African Republic, Nigeria, Sudan and Uganda.ResultsModelled age-specific OSD and OOD prevalence at baseline align well with reported prevalence estimates across the simulated range of endemicity levels but underestimate irreversible OSD in older age groups. Under MDA, we capture trends in infection prevalence, severe itch and irreversible OSD but underestimate reductions in RSD and blindness prevalence.ConclusionsIntegrating morbidity outcomes into transmission dynamics modelling will help improve estimates of onchocerciasis disease burden and inform the effectiveness and cost-effectiveness of current and alternative interventions.
AU - Dixon-Zegeye,M
AU - Ramani,A
AU - Walker,M
AU - Stapley,J
AU - Murdoch,ME
AU - Murdoch,IE
AU - Ozoh,GA
AU - Mosser,JF
AU - Basanez,M-G
DO - 10.1038/s43856-026-01464-2
PY - 2026///
SN - 2730-664X
TI - Modelling of onchocerciasis-associated skin and ocular disease and the impact of ivermectin treatment
T2 - Communications Medicine
UR - http://dx.doi.org/10.1038/s43856-026-01464-2
VL - 6
ER -
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk